SOCIETY FOR IMMUNOTHERAPY OF CANCER INC
555 E WELLS STREET 1100, MILWAUKEE, WI 53202 www.sitcancer.org

Total Revenue
$13,947,573
Total Expenses
$11,066,744
Net Assets
$16,797,671

Organizations Filed Purposes: TO IMPROVE CANCER PATIENT OUTCOMES BY ADVANCING THE SCIENCE, DEVELOPMENT AND APPLICATION OF CANCER IMMUNOLOGY AND IMMUNOTHERAPY THROUGH OUR CORE VALUES OF INTERACTION/INTEGRATION, INNOVATION, TRANSLATION AND LEADERSHIP IN THE FIELD. SITC AIMS TO MAKE CANCER IMMUNOTHERAPY A STANDARD OF CARE AND THE WORD "CURE" A REALITY FOR CANCER PATIENTS EVERYWHERE.

SITC's 34th Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects. The intended audience for this program included U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

WORKSHOP / CONNECTED / PRIMER / WIC/ INDUSTRY / WINTER / WIN / INTERIM PROGRAM / SPAKATHON PROGRAM / JOURNAL / OTHER PROGRAM SERVICES

THE ADVANCES IN CANCER IMMUNOTHERAPY (ACI) REGIONAL SERIES HOSTED FIFTEEN REGIONAL CME-, CNE- AND CPE-CERTIFIED PROGRAMS IN 2019. THE SERIES WAS DESIGNED TO PROVIDE EDUCATION TO PATIENT CARE PROVIDERS AND OTHERS WHO WISH TO LEARN THE BASIC PRINCIPLES OF TUMOR IMMUNOLOGY AND IMMUNOTHERAPY, AND TO IMPROVE THEIR ABILITY TO INTEGRATE IMMUNOTHERAPY INTO STATE-OF-THE-ART CLINICAL MANAGEMENT FOR THEIR PATIENTS. THIS INTENDED AUDIENCE INCLUDES CLINICAL ONCOLOGISTS, REGISTERED NURSES, NURSE PRACTITIONERS, PHARMACISTS, EMERGENCY PHYSICIANS, ALLIED HEALTH PROFESSIONALS, OTHER PATIENT CARE PROVIDERS, STUDENTS AND PATIENT ADVOCATES.

Executives Listed on Filing

Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing

NameTitleHours Per WeekTotal Salary
Leisha A Emens Md PhdDirector1$3,000
Douglas Mcneel Md PhdDirector1$2,000
Lisa H Butterfield PhdIMM. PAST PRES.1$1,000
Ana Carrizosa Anderson PhdDirector1$0
Daniel S Chen Md PhdDirector1$0
David Kaufman Md PhdDirector1$0
Patrick Hwu MdVice President5$0
Mario Sznol MdPresident5$0
Kim A Margolin MdSECR/TREASURER5$0
Paolo A Ascierto MdDirector1$0
Kristen Hege MdDirector1$0
Marcela V Maus Md PhdDirector1$0
Charles G Drake Md PhdDirector1$0

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202033169349302173_public.xml